Spago Nanomedical is a Swedish biotechnology company developing products for precision imaging and radionuclide treatment of cancer and other devastating diseases. The company´s two main development programs, SpagoPix and Tumorad, are based on a unique and proprietary platform for physiological accumulation of optimized and functionalized polymeric particles in tumors. Candidate drug SN132D is a gadolinium-free contrast agent for precision magnetic resonance imaging (MRI) with exceptionally high signal strength. By selective physiological accumulation in tumor tissue, SpagoPix meets a well recognized need for significantly improved soft tissue tumor imaging with further potential in inflammatory endometriosis. Candidate drug 177Lu-SN201 is a novel radiopharmaceutical nanoprticle with potential to expand the scope of radionuclide therapy in solid tumor indications not currently targetable by other modalities, as monotherapy or in combinations with established treatments.
Looking for a particular Spago Nanomedical AB employee's phone or email?
Spago Nanomedical AB Questions
The Spago Nanomedical AB annual revenue was $1 million in 2026.
Mats Hansen is the CEO of Spago Nanomedical AB.
6 people are employed at Spago Nanomedical AB.
Spago Nanomedical AB is based in Lund, Skane.
The NAICS codes for Spago Nanomedical AB are [541713, 541, 54171, 54, 5417].
The SIC codes for Spago Nanomedical AB are [87, 873].
Top Spago Nanomedical AB Employees
-
Mats Hansen
CEO at Spago Nanomedical AB
Malmö, SE1 -
22
-
4
Related Companies
